Francesco Rametta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francesco Rametta has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Chiara Cavallino
Division of Cardiology Sant'Andrea Hospital Vercelli Italy
3 shared publications - Alessandro Lupi
SC Cardiologia Divison, ASL Verbano-Cusio-OssolaVerbania and Domodossola Hospitals, Verbania, Italy
2 shared publications - Andrea Rognoni
Coronary Care Unit and Catheterization Laboratory, A.O.U. Maggiore della Carità, Novara, Italy
2 shared publications Angelo Sante Bongo
2 shared publications- Fabrizio Ugo
Cardiology Division, Sant’Andrea Hospital
2 shared publications - Mario Matta
A.O.U. San Giovanni Battista Molinette, Division of Cardiology, Cardiovascular and Thoracic Department , Turin , Italy
2 shared publications
Latest Publications
- 23 May 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (27) , 2500
The glorious era of interventional cardiology
This fluoroscopy image shows the sensational angiography of an 86-year-old man, a former national marathon champion, affected by heart failure with reduced ejection fraction (EF 38%) and multiple comorbidities, including permanent atrial fibrillation, chronic coronary syndrome, severe aortic stenosis, and secondary mitral regurgitation. In the last decades, several percutaneous procedures were performed, such as coronary angioplasty with implantation of drug-eluting stents (DES) in the left anterior descending artery and right coronary artery (A), transcatheter aortic valve implantation (TAVI) with CoreValve™ Evolut 34 mm (B) because of severe aortic stenosis, and CRT-P Medtronic™ Percepta Quad implantation (C) because of left bundle branch block and systolic ventricular dysfunction. Furthermore, he underwent percutaneous left atrial appendage closure (LAAC) with Amplatzer™ Amulet™ 28 mm (D) due to an ischaemic stroke that occurred during anticoagulant therapy with vitamin K antagonist (VKA), and mitral transcatheter edge-to-edge repair (TEER) with implantation of two MitraClip™ G4 NTW (E) because of functional severe mitral valve regurgitation. Finally, the severe left ventricular dysfunction and the elevated number of hospitalizations despite the optimal medical therapy made it necessary to implant the CardioMEMS™ (F) in the left pulmonary artery to optimize clinical management. This has made it possible to reduce hospitalizations from 13 to 4 per year. The patient is now being evaluated for tricuspid valve intervention due to massive and clinically relevant tricuspid regurgitation.
- 23 May 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (27) , 2500
The glorious era of interventional cardiology
This fluoroscopy image shows the sensational angiography of an 86-year-old man, a former national marathon champion, affected by heart failure with reduced ejection fraction (EF 38%) and multiple comorbidities, including permanent atrial fibrillation, chronic coronary syndrome, severe aortic stenosis, and secondary mitral regurgitation. In the last decades, several percutaneous procedures were performed, such as coronary angioplasty with implantation of drug-eluting stents (DES) in the left anterior descending artery and right coronary artery (A), transcatheter aortic valve implantation (TAVI) with CoreValve™ Evolut 34 mm (B) because of severe aortic stenosis, and CRT-P Medtronic™ Percepta Quad implantation (C) because of left bundle branch block and systolic ventricular dysfunction. Furthermore, he underwent percutaneous left atrial appendage closure (LAAC) with Amplatzer™ Amulet™ 28 mm (D) due to an ischaemic stroke that occurred during anticoagulant therapy with vitamin K antagonist (VKA), and mitral transcatheter edge-to-edge repair (TEER) with implantation of two MitraClip™ G4 NTW (E) because of functional severe mitral valve regurgitation. Finally, the severe left ventricular dysfunction and the elevated number of hospitalizations despite the optimal medical therapy made it necessary to implant the CardioMEMS™ (F) in the left pulmonary artery to optimize clinical management. This has made it possible to reduce hospitalizations from 13 to 4 per year. The patient is now being evaluated for tricuspid valve intervention due to massive and clinically relevant tricuspid regurgitation.
- Open Access
- 26 April 2022
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
- Vol. 8, e15
Pulmonary Artery Catheter Monitoring in Patients with Cardiogenic Shock: Time for a Reappraisal?
Cardiogenic shock represents one of the most dramatic scenarios to deal with in intensive cardiology care and is burdened by substantial short-term mortality. An integrated approach, including timely diagnosis and phenotyping, along with a well-established shock team and management protocol, may improve survival. The use of the Swan-Ganz catheter could play a pivotal role in various phases of cardiogenic shock management, encompassing diagnosis and haemodynamic characterisation to treatment selection, titration and weaning. Moreover, it is essential in the evaluation of patients who might be candidates for long-term heart-replacement strategies. This review provides a historical background on the use of the Swan-Ganz catheter in the intensive care unit and an analysis of the available evidence in terms of potential prognostic implications in this setting.
- 26 April 2022
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
- Vol. 8, e15
Open AccessPulmonary Artery Catheter Monitoring in Patients with Cardiogenic Shock: Time for a Reappraisal?
Cardiogenic shock represents one of the most dramatic scenarios to deal with in intensive cardiology care and is burdened by substantial short-term mortality. An integrated approach, including timely diagnosis and phenotyping, along with a well-established shock team and management protocol, may improve survival. The use of the Swan-Ganz catheter could play a pivotal role in various phases of cardiogenic shock management, encompassing diagnosis and haemodynamic characterisation to treatment selection, titration and weaning. Moreover, it is essential in the evaluation of patients who might be candidates for long-term heart-replacement strategies. This review provides a historical background on the use of the Swan-Ganz catheter in the intensive care unit and an analysis of the available evidence in terms of potential prognostic implications in this setting.
- Open Access
- 1 January 2021
- Published by Open Access Text Pvt, Ltd. in Nephrology and Renal Diseases
- Vol. 6 (1)
LAA closure in pre-dialytic and dialytic patients: A case report and mini review of literature
OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.
- 1 January 2021
- Published by Open Access Text Pvt, Ltd. in Nephrology and Renal Diseases
- Vol. 6 (1)
Open AccessLAA closure in pre-dialytic and dialytic patients: A case report and mini review of literature
OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in Research Reports in Clinical Cardiology
- Vol. ume 11, 1-6
Atrioventricular Nodal Reentrant Tachycardia: Current Perspectives
Atrioventricular nodal reentrant tachycardia (AVNRT) is the most common, highly symptomatic paroxysmal supraventricular tachycardia. Despite pharmacological treatment and vagal maneuvers for acute termination, catheter ablation has emerged as the first line treatment for the cure of AVNRT episodes. Several studies during recent years have investigated the efficacy, safety and long-term effect of both radiofrequency ablation and cryoablation of the slow pathway for the treatment of AVNRT. Innovations such as mapping systems and dedicated catheters have contributed by extending the indication to AVNRT ablation, even in particular subset populations such as children and congenital heart disease patients. We performed this review with the aim aim of summarizing and discussing current perspectives on the treatment of AVNRT, mainly focusing on catheter ablation energy sources and long-term results.
- 1 January 2020
- Published by Taylor & Francis in Research Reports in Clinical Cardiology
- Vol. ume 11, 1-6
Open AccessAtrioventricular Nodal Reentrant Tachycardia: Current Perspectives
Atrioventricular nodal reentrant tachycardia (AVNRT) is the most common, highly symptomatic paroxysmal supraventricular tachycardia. Despite pharmacological treatment and vagal maneuvers for acute termination, catheter ablation has emerged as the first line treatment for the cure of AVNRT episodes. Several studies during recent years have investigated the efficacy, safety and long-term effect of both radiofrequency ablation and cryoablation of the slow pathway for the treatment of AVNRT. Innovations such as mapping systems and dedicated catheters have contributed by extending the indication to AVNRT ablation, even in particular subset populations such as children and congenital heart disease patients. We performed this review with the aim aim of summarizing and discussing current perspectives on the treatment of AVNRT, mainly focusing on catheter ablation energy sources and long-term results.
- 4 October 2016
- Published by Bentham Science Publishers Ltd. in Reviews on Recent Clinical Trials
- Vol. 11 (4) , 280-283
Ticagrelor: Long-Term Therapy in Patients with Coronary Artery Disease
Introduction: Atherothrombosis and coronary artery disease affect more than 13 million individuals only in the United States, about 8 millions in Europe and are the major causes of death worldwide. In particular chronic stable angina impairs patient quality of life, is associated with an important health spending and increased patient mortality; it is a prominent symptom of coronary artery disease (CAD), the latter being prevalent worldwide in patients. A key role in pathophysiology of cardiovascular acute events is played by activated platelets. Aspirin and adenosine diphosphate antagonist in addition to it is recommended for 1 year for reduction of cardiovascular events in patients with prior myocardial infarction with a weak recommendation to continue thereafter. P2Y12 receptor antagonists, in addition to aspirin, have been shown in the last years, to reduce ischemic events in patients with acute coronary syndrome but their role in secondary prevention is still new and unclear. The aim of our paper is to review the long-term effect of therapy with ticagrelor on the basis of recent evidence based data. Methods: We performed an online search on the major search engines. All the randomized controlled trials were summarized in the table. Results: We included in our paper six randomized controlled trials and we mentioned about ten post – hoc analysis, sub studies and registries. All studies included the type the therapy and a mid or long term clinical follow up. Conclusions: The studies reported in our paper and in particular PEGASUS – TIMI 54 study showed the merit to placing attention of prevention secondary ischemic events after acute coronary syndrome in the context of treatment with dual anti – platelet therapy; it proved a clinical benefit in patients treated with ticagrelor (60 mg x 2) for 3 years. Nevertheless, the effectiveness of these results cannot be generalized to patients with higher bleeding risk or low ischemic risk. In fact prolonged therapy with ticagrelor 60 mg in combination with aspirin could be considered valuable in patients with repeated acute ischemic events or with several coronary revascularizations over time (especially in patients with lower bleeding risk).
- 4 October 2016
- Published by Bentham Science Publishers Ltd. in Reviews on Recent Clinical Trials
- Vol. 11 (4) , 280-283
Ticagrelor: Long-Term Therapy in Patients with Coronary Artery Disease
Introduction: Atherothrombosis and coronary artery disease affect more than 13 million individuals only in the United States, about 8 millions in Europe and are the major causes of death worldwide. In particular chronic stable angina impairs patient quality of life, is associated with an important health spending and increased patient mortality; it is a prominent symptom of coronary artery disease (CAD), the latter being prevalent worldwide in patients. A key role in pathophysiology of cardiovascular acute events is played by activated platelets. Aspirin and adenosine diphosphate antagonist in addition to it is recommended for 1 year for reduction of cardiovascular events in patients with prior myocardial infarction with a weak recommendation to continue thereafter. P2Y12 receptor antagonists, in addition to aspirin, have been shown in the last years, to reduce ischemic events in patients with acute coronary syndrome but their role in secondary prevention is still new and unclear. The aim of our paper is to review the long-term effect of therapy with ticagrelor on the basis of recent evidence based data. Methods: We performed an online search on the major search engines. All the randomized controlled trials were summarized in the table. Results: We included in our paper six randomized controlled trials and we mentioned about ten post – hoc analysis, sub studies and registries. All studies included the type the therapy and a mid or long term clinical follow up. Conclusions: The studies reported in our paper and in particular PEGASUS – TIMI 54 study showed the merit to placing attention of prevention secondary ischemic events after acute coronary syndrome in the context of treatment with dual anti – platelet therapy; it proved a clinical benefit in patients treated with ticagrelor (60 mg x 2) for 3 years. Nevertheless, the effectiveness of these results cannot be generalized to patients with higher bleeding risk or low ischemic risk. In fact prolonged therapy with ticagrelor 60 mg in combination with aspirin could be considered valuable in patients with repeated acute ischemic events or with several coronary revascularizations over time (especially in patients with lower bleeding risk).
- 21 May 2014
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 12 (7) , 913-917
Aortic counterpulsation in cardiogenic shock during acute myocardial infarction
Intra-aortic balloon counterpulsation is the most widely used form of mechanical hemodynamic support in the setting of cardiogenic shock due to ST-segment elevation myocardial infarction (STEMI). Intra-aortic balloon pump (IABP) is also strongly recommended (class 1b) in the current European guidelines for treatment of STEMI. The evidence of a possible benefit of IABP in this setting is based mainly on registry data and a few randomized trials. Cardiogenic shock and subsequent death due to STEMI result from three factors: hemodynamic deterioration, occurrence of multiorgan dysfunction and systemic inflammatory response. IABP does not cause an immediate improvement in blood pressure, but the recent SHOCK II trial shows positive effects on multiorgan dysfunction. Some experimental and clinical studies have indicated that IABP results in hemodynamic benefits as a result of afterload reduction and diastolic augmentation with improvement of coronary perfusion. However, the effect on cardiac output is modest and may not be sufficient to reduce mortality. Furthermore we can say that the use of IABP before coronary revascularization in the setting of STEMI complicated with cardiogenic shock may make the interventional procedure safer by improving left ventricular unloading. The purpose of the present review is to clarify the state of the art on this topic.
- 21 May 2014
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 12 (7) , 913-917
Aortic counterpulsation in cardiogenic shock during acute myocardial infarction
Intra-aortic balloon counterpulsation is the most widely used form of mechanical hemodynamic support in the setting of cardiogenic shock due to ST-segment elevation myocardial infarction (STEMI). Intra-aortic balloon pump (IABP) is also strongly recommended (class 1b) in the current European guidelines for treatment of STEMI. The evidence of a possible benefit of IABP in this setting is based mainly on registry data and a few randomized trials. Cardiogenic shock and subsequent death due to STEMI result from three factors: hemodynamic deterioration, occurrence of multiorgan dysfunction and systemic inflammatory response. IABP does not cause an immediate improvement in blood pressure, but the recent SHOCK II trial shows positive effects on multiorgan dysfunction. Some experimental and clinical studies have indicated that IABP results in hemodynamic benefits as a result of afterload reduction and diastolic augmentation with improvement of coronary perfusion. However, the effect on cardiac output is modest and may not be sufficient to reduce mortality. Furthermore we can say that the use of IABP before coronary revascularization in the setting of STEMI complicated with cardiogenic shock may make the interventional procedure safer by improving left ventricular unloading. The purpose of the present review is to clarify the state of the art on this topic.